Monte Rosa Therapeutics, Inc.
GLUE
$18.15
-$0.53-2.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -194.92% | -443.34% | -13.50% | 59.44% | 246.66% |
| Total Depreciation and Amortization | 1.91% | 7.35% | 1.90% | 19.55% | -2.78% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 18.84% | 14.13% | 24.70% | 11.57% | -9.19% |
| Change in Net Operating Assets | 100.14% | -103.07% | 5,098.60% | -881.44% | -664.73% |
| Cash from Operations | 17.86% | -133.36% | 578.37% | -25.04% | -19.20% |
| Capital Expenditure | -17.71% | -319.13% | -63.16% | 16.17% | -14.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -162.70% | -109.35% | 1.68% | 145.69% | -977.83% |
| Cash from Investing | -160.40% | -110.60% | 1.03% | 141.41% | -1,117.24% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,496,485.71% | 4,831.09% | 2,220.00% | -99.29% | -94.31% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2,345,150.00% | 4,772.37% | 2,220.00% | -99.63% | -94.31% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 120.57% | -179.54% | 728.35% | -199.26% | -419.16% |